Michael Lutteropp
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
An Innovative Approach to Optimize First-In-Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T-Cell Engagers: Experience from A Solid Tumor Bispecific T-Cell Engager.
Journal: Clinical pharmacology and therapeutics
Published: March 19, 2024
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule.
Journal: Molecular cancer therapeutics
Published: March 19, 2021
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Journal: Journal for immunotherapy of cancer
Published: August 03, 2018
Initial seeding of the embryonic thymus by immune-restricted lympho-myeloid progenitors.
Journal: Nature immunology
Published: July 03, 2016
Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing.
Journal: Nature immunology
Published: November 26, 2015
Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy.
Journal: Nature
Published: August 15, 2012
Dicer is selectively important for the earliest stages of erythroid development.
Journal: Blood
Published: August 08, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026